[1] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China [J]. J Hepatol, 2009, 50(1): 204-210. [2] Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment [J]. Curr Diab Rep, 2008, 8(1): 25-30. [3] Sourianarayanane A, Pagadala MR, Kirwan JP. Management of non-alcoholic fatty liver disease [J]. Minerva Gastroenterol Dietol, 2013,59(1): 69-87. [4] American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults [J]. Med Sci Sports Exerc, 2009, 41(3): 687-708. [5] Li J, Chi Y, Wang C, et al. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway [J]. Hepatology, 2011, 53(6):1906-1916. [6] Yang J, Wang C, Li J, et al. PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells [J]. FEBS Lett, 2009, 583(18): 3009-3015. [7] Day CP. Pathogenesis of steatohepatitis [J]. Best Pract Res Clin Gastroenterol, 2002,16(5): 663-678. [8] van der Heijden GJ, kWang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents [J]. Obesity (Silver Spring), 2010, 18(2): 384-390. [9] Sullivan S,Kirk EP, Mittendorfer B, et al. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease [J]. Hepatology, 2012, 55(6): 1738-1745. [10]Iizuka K, Miller B, Uyeda K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice [J]. Am J Physiol Endocrinol Metab, 2006, 291(2): E358-364. [11]Dentin R, Benhamed F, Hainault I, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice [J]. Diabetes, 2006, 55(8): 2159-2170. [12]Guinez, C., et al., O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver [J]. Diabetes, 2011, 60(5):1399-1413.
|